Longevity · Khavinson peptide · Compounded 503A
Epithalon: the tetrapeptide that activates telomerase.
Epithalon (also Epitalon) is a synthetic tetrapeptide — Ala-Glu-Asp-Gly — developed by Vladimir Khavinson at the St. Petersburg Institute of Bioregulation. It is the most studied of the 'Khavinson peptides' and is best known for activating telomerase in human somatic cells and supporting pineal-driven circadian function in older adults.
What Epithalon is
Epithalon is a synthetic tetrapeptide (Ala-Glu-Asp-Gly) developed by Professor Vladimir Khavinson and the St. Petersburg Institute of Bioregulation and Gerontology in Russia. It is a synthetic version of the active fragment of epithalamin — a polypeptide complex isolated from the pineal gland.
The Khavinson group has published over four decades of research on short bioregulatory peptides, with epithalon as the most extensively studied of the longevity-focused entries. Russian-language clinical trials extend back to the 1990s; English-language publications became more frequent in the 2000s and 2010s.
Epithalon is not FDA-approved. It is compounded by licensed 503A pharmacies and prescribed off-label as part of longevity protocols, typically in periodic short courses rather than continuous use.
How it works
Epithalon's most-cited effect is activation of telomerase — the enzyme that maintains telomere length on chromosomes. Khavinson et al. demonstrated telomerase induction in human somatic (non-germline) cells in culture, including extension of cellular replicative capacity beyond the Hayflick limit in some experimental conditions.
Beyond telomerase, epithalon appears to support pineal function. The pineal gland — and its principal hormone melatonin — regulates circadian rhythm and atrophies with age. Epithalon administration has been associated with restored melatonin rhythmicity in older patients.
Russian long-term studies have reported reductions in age-related mortality markers and improvements in homeostatic regulation in elderly cohorts. The English-language replication base is smaller than the original Russian literature; honest framing matters here.
What patients use it for
Telomerase activation
The most-cited finding — epithalon induces telomerase activity in human somatic cells. The translational significance in living humans is still being clarified.
Pineal and circadian support
Restored melatonin rhythmicity has been reported in elderly cohorts treated with epithalon. Sleep quality improvements are among the most commonly reported subjective effects.
Antioxidant capacity
Reductions in lipid peroxidation markers and improvements in antioxidant enzyme activity have been reported in aged-animal studies.
Cellular aging research
Epithalon is one of the few clinically-used peptides with a substantive longevity-research case. Whether the in vitro telomerase effect translates to whole-organism healthspan extension is the active research question.
Evidence summary
Khavinson VK et al. have published the foundational work on epithalon's telomerase activation — including extension of human somatic cell replicative capacity in vitro.
Anisimov VN et al. published long-term studies in elderly cohorts in St. Petersburg reporting reduced mortality markers over multi-year follow-up with periodic epithalon courses.
Independent replication outside the Khavinson group is limited. Off-label clinical use exceeds the strength of the English-language RCT base. Physicians and patients should discuss this candidly when considering epithalon.
Dosing and clinical context
General clinical context only. Kindr Health physicians determine the appropriate dose and protocol for each patient based on history and labs. This is not a prescription or dosing recommendation.
Typical clinical protocols use 5–10 mg subcutaneously daily for 10–20 days, then no treatment for several months. The 'pulsed course' rather than continuous dosing is characteristic of how Khavinson protocols are designed.
Most patients run 1–2 courses per year. Continuous daily use is not the standard approach in the Russian literature.
Injection is straightforward — subcutaneous abdomen or thigh, small volume, minimal supplies. Most patients self-administer after initial instruction.
Safety and contraindications
Across the published clinical and observational base, epithalon is reported as very well-tolerated. Mild injection-site reactions are the most common report.
Contraindications: pregnancy, active malignancy, hormone-sensitive cancers (relative — discuss with physician). The telomerase activation mechanism is theoretically concerning in active cancer.
Off-label compounded use under physician supervision through a licensed 503A pharmacy. Not FDA-approved.
Who it's typically considered for
- Adults in midlife or older seeking a periodic longevity-axis course
- Patients with sleep / circadian disturbance — particularly age-related
- Patients already on or considering NAD+ or MOTS-c (epithalon is often layered with other longevity-axis interventions in short courses)
- Patients comfortable with the honest evidence framing — strong mechanistic case, mixed strength of independent clinical replication
Frequently asked questions
Does epithalon actually extend telomeres in humans?
Epithalon activates telomerase in human somatic cells in vitro. Whether this translates to measurable telomere extension and meaningful healthspan or lifespan extension in living humans is not yet established by independent randomized trials. The strongest claim that can honestly be made is: it activates the enzyme; the in vivo human outcome is an active research question.
Is epithalon FDA-approved?
No. Epithalon is not FDA-approved for any indication. Compounded epithalon is prepared by licensed 503A pharmacies under physician prescription for off-label use.
Why is epithalon dosed in courses rather than daily?
The Khavinson protocols — which inform most current clinical use — are based on the observation that bioregulatory peptide effects persist for months after a short intensive course. Continuous daily use is not the standard approach in the original Russian literature.
How long until I notice anything?
Sleep is often the earliest subjective change — many patients report improved sleep quality within the first 1–2 weeks of a course. Energy and cognitive shifts, when reported, typically appear later in the course or in the weeks after.
Can I take epithalon with HRT?
Yes. Epithalon and HRT address different systems and are commonly layered. Your kindr physician reviews your full medication list before prescribing.
Is epithalon safe in cancer survivors?
The telomerase activation mechanism is theoretically concerning in active cancer. In cancer survivors with no active disease, use should be discussed with both the prescribing physician and the patient's oncologist.
Is epithalon the same as epitalon or epithalamin?
Epithalon and epitalon are two spellings of the same synthetic tetrapeptide (Ala-Glu-Asp-Gly). Epithalamin is the original natural polypeptide complex isolated from the pineal gland — epithalon is the synthetic active fragment derived from it.
Sources
- Khavinson VK et al. Peptide promotes overcoming of the division limit in human somatic cell. Bulletin of Experimental Biology and Medicine (2003). — pubmed.ncbi.nlm.nih.gov/14564372
- Khavinson VK, Bondarev IE, Butyugov AA. Epithalon peptide induces telomerase activity and telomere elongation in human somatic cells. Bulletin of Experimental Biology and Medicine (2003). — pubmed.ncbi.nlm.nih.gov/14534640
- Anisimov VN, Khavinson VK. Peptide bioregulation of aging: results and prospects. Biogerontology (2010). — pubmed.ncbi.nlm.nih.gov/19921437
- Korkushko OV et al. Geroprotective effect of epithalamin and epitalon in elderly subjects. Bulletin of Experimental Biology and Medicine (2007). — pubmed.ncbi.nlm.nih.gov/18225264
Considering Epithalon?
A Kindr Health physician reviews every longevity intake — peptides are prescribed only when medically indicated based on your history and labs. There is no charge for the initial review.
Start your longevity intake →Related peptides
Medically reviewed by Dr. Ana Lisa Carr, MD, MBA
Board-Certified Family Medicine Physician · Lead Provider / Medical Reviewer
NPI 1689841744 · Last reviewed: May 10, 2026
Last reviewed May 10, 2026. Compounded medications are prepared by FDA-registered 503A pharmacies and are not FDA-approved drug products. Prescriptions require a clinical evaluation; a Kindr Health physician determines eligibility. Not for use in pregnancy. This page provides educational information and is not medical advice.